ATE266649T1 - Benzofurazan derivate zur modelierung der ampa- rezeptor-aktivität - Google Patents

Benzofurazan derivate zur modelierung der ampa- rezeptor-aktivität

Info

Publication number
ATE266649T1
ATE266649T1 AT98906358T AT98906358T ATE266649T1 AT E266649 T1 ATE266649 T1 AT E266649T1 AT 98906358 T AT98906358 T AT 98906358T AT 98906358 T AT98906358 T AT 98906358T AT E266649 T1 ATE266649 T1 AT E266649T1
Authority
AT
Austria
Prior art keywords
ampa receptor
modeling
receptor activity
receptors
ampa
Prior art date
Application number
AT98906358T
Other languages
English (en)
Inventor
Gary A Rogers
Christopher M Marrs
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE266649T1 publication Critical patent/ATE266649T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Luminescent Compositions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT98906358T 1997-02-13 1998-02-13 Benzofurazan derivate zur modelierung der ampa- rezeptor-aktivität ATE266649T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses
PCT/US1998/002713 WO1998035950A1 (en) 1997-02-13 1998-02-13 Benzofurazan compounds which enhance ampa receptor activity

Publications (1)

Publication Number Publication Date
ATE266649T1 true ATE266649T1 (de) 2004-05-15

Family

ID=25177504

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04075259T ATE326221T1 (de) 1997-02-13 1998-02-13 Benzofurazanderivate und deren verwendung zur verbesserung glutaminerger synaptischer antworten
AT98906358T ATE266649T1 (de) 1997-02-13 1998-02-13 Benzofurazan derivate zur modelierung der ampa- rezeptor-aktivität

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04075259T ATE326221T1 (de) 1997-02-13 1998-02-13 Benzofurazanderivate und deren verwendung zur verbesserung glutaminerger synaptischer antworten

Country Status (24)

Country Link
US (3) US6110935A (de)
EP (2) EP0960105B1 (de)
JP (1) JP4446023B2 (de)
KR (1) KR100544295B1 (de)
CN (1) CN1085206C (de)
AT (2) ATE326221T1 (de)
AU (1) AU737802C (de)
BR (1) BR9807333B1 (de)
CA (1) CA2279319C (de)
CZ (1) CZ299765B6 (de)
DE (2) DE69823803T2 (de)
DK (2) DK0960105T3 (de)
ES (2) ES2264078T3 (de)
GB (1) GB2325225B (de)
HU (1) HUP0002303A3 (de)
ID (1) ID22342A (de)
IL (1) IL131200A (de)
NO (1) NO318935B1 (de)
NZ (1) NZ336980A (de)
PL (1) PL199135B1 (de)
PT (2) PT960105E (de)
RU (1) RU2189984C2 (de)
TR (1) TR199901941T2 (de)
WO (1) WO1998035950A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (de) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
AU2002366756A1 (en) * 2001-12-20 2003-07-09 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
CA2509251A1 (en) * 2003-01-13 2004-07-29 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
US7385061B2 (en) * 2003-05-23 2008-06-10 Basilea Pharmaceutica Ag Furazanobenzimidazoles
EP1715863B1 (de) * 2004-01-26 2012-05-09 Cortex Pharmaceuticals, Inc. Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren
JP2010501597A (ja) * 2006-08-31 2010-01-21 ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ 正のアロステリックａｍｐａ受容体モジュレーターを用いて呼吸抑制を阻害する方法
AP2009004915A0 (en) * 2007-01-03 2009-08-31 Cortex Pharma Inc 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
PL2144506T3 (pl) * 2007-01-03 2012-04-30 Servier Lab 3-podstawiony-[1,2,3]-benzotriazynon jako związek do wzmacniania odpowiedzi glutaminianergicznych
AU2008254960B2 (en) * 2007-05-17 2014-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
CN101896183B (zh) 2007-08-10 2013-11-27 科泰克斯药品公司 用于增强谷氨酸能突触反应的二环酰胺
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
MX2011008060A (es) * 2009-02-02 2011-09-09 Cortex Pharma Inc Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
EP2801377B1 (de) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel enthaltend Zellen zur lokalen Freisetzung von Wachstumsfaktoren zur Rückgewinnung der Bewegungsfähigkeit nach einem Schlaganfall
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1Ｈ-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
CA2915405A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders
CN107286114B (zh) * 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
PT651746E (pt) * 1992-07-24 2002-09-30 Univ California Drogas que intensificam as respostas sinapticas mediadas por receptores de ampa
DK0709384T3 (da) * 1994-10-31 1999-08-23 Merck Patent Gmbh Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Also Published As

Publication number Publication date
JP2001512459A (ja) 2001-08-21
DE69823803T2 (de) 2005-04-14
US6110935A (en) 2000-08-29
DE69823803D1 (de) 2004-06-17
DE69834590D1 (de) 2006-06-22
CA2279319A1 (en) 1998-08-20
EP0960105B1 (de) 2004-05-12
ES2221152T3 (es) 2004-12-16
GB2325225A (en) 1998-11-18
US20020055508A1 (en) 2002-05-09
BR9807333A (pt) 2000-04-18
DK1428534T3 (da) 2006-06-12
NO993768D0 (no) 1999-08-04
NO318935B1 (no) 2005-05-30
HUP0002303A3 (en) 2002-09-30
ATE326221T1 (de) 2006-06-15
AU737802C (en) 2005-05-12
AU6159998A (en) 1998-09-08
ID22342A (id) 1999-09-30
EP0960105A1 (de) 1999-12-01
US6313115B1 (en) 2001-11-06
CZ279599A3 (cs) 2000-01-12
HUP0002303A2 (hu) 2001-04-28
CN1247534A (zh) 2000-03-15
WO1998035950A1 (en) 1998-08-20
JP4446023B2 (ja) 2010-04-07
ES2264078T3 (es) 2006-12-16
DE69834590T2 (de) 2007-04-26
NO993768L (no) 1999-09-23
NZ336980A (en) 2000-08-25
IL131200A0 (en) 2001-01-28
RU2189984C2 (ru) 2002-09-27
PT960105E (pt) 2004-09-30
CA2279319C (en) 2008-08-05
GB9809221D0 (de) 1998-07-01
PL335058A1 (en) 2000-03-27
DK0960105T3 (da) 2004-08-30
EP1428534B1 (de) 2006-05-17
KR20000071082A (ko) 2000-11-25
BR9807333B1 (pt) 2011-10-18
PL199135B1 (pl) 2008-08-29
GB2325225A8 (en) 1999-02-17
PT1428534E (pt) 2006-07-31
CZ299765B6 (cs) 2008-11-19
IL131200A (en) 2005-06-19
CN1085206C (zh) 2002-05-22
US6730677B2 (en) 2004-05-04
AU737802B2 (en) 2001-08-30
TR199901941T2 (xx) 1999-12-21
EP1428534A1 (de) 2004-06-16
KR100544295B1 (ko) 2006-01-23
GB2325225B (en) 1999-03-03

Similar Documents

Publication Publication Date Title
ATE266649T1 (de) Benzofurazan derivate zur modelierung der ampa- rezeptor-aktivität
DE69811363T2 (de) Piperazin-derivate und ihre verwendung als entzündungshemmende mittel
NO302172B1 (no) Quinuclidin-derivater
ATE451362T1 (de) Salze von liponsaürederivaten und deren verwendung bei der behandlung von krankheiten
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
DK0891365T3 (da) Benzoxaziner til forstærkning af synaptiske responser
ATE229806T1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
ATE261306T1 (de) Benzoxazin-derivate zur erhöhung der synaptischen reaktion
MX14957A (es) Nuevos derivados de tetrazol y procedimiento para su preparacion.
ATE247472T1 (de) Acylbenzoxazine zur erhöhung der synaptischen reaktion(en)
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
ES2169723T3 (es) Derivados de piridinio y su uso para determinar trastornos del tejido conectivo en seres humanos y animales.
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
DE3669159D1 (de) Triazinderivate, verfahren zur herstellung dieser derivate und herbizide, welche diese derivate als wirksame komponente enthalten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0960105

Country of ref document: EP